Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: A proof-of-concept study

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 6, 2014, Pages 713-722

  Kristensen, K E ^a   Zhu, H J ^b   Wang, X ^b   Gislason, G H ^a,c   Torp Pedersen, C ^d   Rasmussen, H B ^e   Markowitz, J S ^f   Hansen, P R ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

^e Mental Health Centre Sct Hans   (Denmark)

^f UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; BIS(4 NITROPHENYL) PHOSPHATE; CAPTOPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; ANTITHROMBOCYTIC AGENT; CARBOXYLESTERASE; CES1 PROTEIN, HUMAN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RISK FACTOR; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; CHEMICALLY INDUCED; DRUG INTERACTION; MYOCARDIAL INFARCTION; PHYSIOLOGY; RISK;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOTRANSFORMATION; CARBOXYLIC ESTER HYDROLASES; DRUG INTERACTIONS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RISK; TICLOPIDINE;

EID: 84925550303     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.183     Document Type: Article

References (46)

1. Anderson, J.L. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol. 50, e1-e157 (2007).
2. O'Gara, P.T. et al. ACCF/AHA 2013 guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 61, e78-140.
3. Ahmad, T., Voora, D. & Becker, R.C. The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat. Rev. Cardiol. 8, 560-571 (2011).
4. Kazui, M. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92-99 (2010).
5. Hagihara, K. et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab. Dispos. 37, 2145-2152 (2009).
6. Tang, M. et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther. 319, 1467-1476 (2006).
7. Zhu, H.J., Wang, X., Gawronski, B.E., Brinda, B.J., Angiolillo, D.J. & Markowitz, J.S. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J. Pharmacol. Exp. Ther. 344, 665-672 (2013).
8. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
9. Bates, E.R., Lau, W.C. & Angiolillo, D.J. Clopidogrel-drug interactions. J. Am. Coll. Cardiol. 57, 1251-1263 (2011).
10. Olesen, J.B. et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J. Am. Coll. Cardiol. 57, 409-417 (2011).
11. Lewis, J.P. et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet. Genomics 23, 1-8 (2013).
12. Zhu, H.J., Appel, D.I., Johnson, J.A., Chavin, K.D. & Markowitz, J.S. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem. Pharmacol. 77, 1266-1272 (2009).
13. Thomsen, R., Rasmussen, H.B. & Linnet, K.; INDICES Consortium. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Drug Metab. Dispos. 42, 126-133 (2014).
14. Satoh, T. & Hosokawa, M. Structure, function and regulation of carboxylesterases. Chem. Biol. Interact. 162, 195-211 (2006).
15. Laizure, S.C., Herring, V., Hu, Z., Witbrodt, K. & Parker, R.B. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33, 210-222 (2013).
16. Drummer, O.H., Nicolaci, J. & Iakovidis, D. Biliary excretion and conjugation of diacid angiotensin-converting enzyme inhibitors. J. Pharmacol. Exp. Ther. 252, 1202-1206 (1990).
17. Pang, K.S., Barker, F. 3rd, Cherry, W.F. & Goresky, C.A. Esterases for enalapril hydrolysis are concentrated in the perihepatic venous region of the rat liver. J. Pharmacol. Exp. Ther. 257, 294-301 (1991).
18. Vistoli, G., Pedretti, A., Mazzolari, A. & Testa, B. In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations. Bioorg. Med. Chem. 18, 320-329 (2010).
19. Vertes, V. & Haynie, R. Comparative pharmacokinetics of captopril, enalapril, and quinapril. Am. J. Cardiol. 69, 8C-16C (1992).
20. Kuliczkowski, W. et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J. 30, 426-435 (2009).
21. Sibbing, D., Byrne, R.A., Bernlochner, I. & Kastrati, A. High platelet reactivity and clinical outcome -fact and fiction. Thromb. Haemost. 106, 191-202 (2011).
22. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
23. Frelinger, A.L. 3rd et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J. Am. Coll. Cardiol. 61, 872-879 (2013).
24. Angiolillo, D.J. et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol. 50, 1541-1547 (2007).
25. Angiolillo, D.J. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115, 708-716 (2007).
26. Hosokawa, M. et al. Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes. Drug Metab. Rev. 39, 1-15 (2007).
27. Marsh, S. et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84, 661-668 (2004).
28. Zhu, H.J. et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am. J. Hum. Genet. 82, 1241-1248 (2008).
29. Fukami, T., Takahashi, S., Nakagawa, N., Maruichi, T., Nakajima, M. & Yokoi, T. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab. Dispos. 38, 2173-2178 (2010).
30. Takahashi, S., Katoh, M., Saitoh, T., Nakajima, M. & Yokoi, T. Different inhibitory effects in rat and human carboxylesterases. Drug Metab. Dispos. 37, 956-961 (2009).
31. Shi, D. et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J. Pharmacol. Exp. Ther. 319, 1477-1484 (2006).
32. Zhu, H.J., Appel, D.I., Peterson, Y.K., Wang, Z. & Markowitz, J.S. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology 270, 59-65 (2010).
33. Floyd, C.N., Passacquale, G. & Ferro, A. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin. Pharmacokinet. 51, 429-442 (2012).
34. Wiviott, S.D. et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
35. Cannon, C.P. et al.; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375, 283-293 (2010).
36. Takahashi, M., Pang, H., Kawabata, K., Farid, N.A. & Kurihara, A. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 48, 1219-1224 (2008).
37. Tuffal, G. et al. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb. Haemost. 105, 696-705 (2011).
38. Andersen, T.F., Madsen, M., Jørgensen, J., Mellemkjoer, L. & Olsen, J.H. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan. Med. Bull. 46, 263-268 (1999).
39. Gaist, D., Sørensen, H.T. & Hallas, J. The Danish prescription registries. Dan. Med. Bull. 44, 445-448 (1997).
40. Sørensen, R. et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br. J. Clin. Pharmacol. 66, 875-884 (2008).
41. Lamberts, M. et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 126, 1185-1193 (2012).
42. Cunningham, A., Stein, C.M., Chung, C.P., Daugherty, J.R., Smalley, W.E. & Ray, W.A. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol. Drug Saf. 20, 560-566 (2011).
43. Madsen, M., Davidsen, M., Rasmussen, S., Abildstrom, S.Z. & Osler, M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J. Clin. Epidemiol. 56, 124-130 (2003).
44. Krarup, L.H., Boysen, G., Janjua, H., Prescott, E. & Truelsen, T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 28, 150-154 (2007).
45. Tu, J.V., Austin, P.C., Walld, R., Roos, L., Agras, J. & McDonald, K.M. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J. Am. Coll. Cardiol. 37, 992-997 (2001).
46. Rasmussen, S., Zwisler, A.D., Abildstrom, S.Z., Madsen, J.K. & Madsen, M. Hospital variation in mortality after first acute myocardial infarction in Denmark from 1995 to 2002: lower short-term and 1-year mortality in highvolume and specialized hospitals. Med. Care 43, 970-978 (2005).